key: cord-0309857-smg1x1qw
authors: Bonelli, M.; Mrak, D.; Tobudic, S.; Sieghart, D.; Koblischke, M.; Mandl, P.; Kornek, B.; Simader, E.; Radner, H.; Perkmann, T.; Haslacher, H.; Mayer, M.; Hofer, P.; Redlich, K.; Husar-Memmer, E.; Fritsch-Stork, R.; Thalhammer, R.; Stiasny, K.; Winkler, S.; Smolen, J. S.; Aberle, J. H.; Zeitlinger, M.; Heinz, L. X.; Aletaha, D.
title: Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial
date: 2021-09-08
journal: nan
DOI: 10.1101/2021.09.05.21263125
sha: 539ce374b2d67e6f55a176143cbb75fc4840d038
doc_id: 309857
cord_uid: smg1x1qw

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to conventional COVID-19 vaccination. In this blinded randomized clinical trial (EudraCT 2021-002348-57) we compare the efficacy and safety of an additional booster vaccination with a vector versus mRNA vaccine in non-seroconverted patients. We assigned 60 patients under rituximab treatment, who did not seroconvert after their primary mRNA vaccination with either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), to receive a third dose, either using the same mRNA or the vector vaccine ChAdOx1 nCoV-19 (Oxford-AstraZeneca). Patients were stratified according to the presence of peripheral B-cells. The primary efficacy endpoint was the difference in the SARS-CoV-2 antibody seroconversion rate between vector (heterologous) and mRNA (homologous) vaccinated patients by week four. Key secondary endpoints included the overall seroconversion and cellular immune response; safety was assessed at weeks one and four. Seroconversion rates at week four were comparable between vector (6/27 patients, 22%) and mRNA (9/28, 32%) vaccine (p=0.6). Overall, 27% of patients seroconverted; specific T-cell responses were observed in 20/20 (100%) vector versus 13/16 (81%) mRNA vaccinated patients. Newly induced humoral and/or cellular responses occurred in 9/11 (82%) patients. No serious adverse events, related to immunization, were observed. This enhanced humoral and/or cellular immune response supports an additional booster vaccination in non-seroconverted patients irrespective of a heterologous or homologous vaccination regimen.

The current pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to exponentially rising morbidity and mortality worldwide.

Apart from aggressive quarantine and infection control hygiene measures, the most effective way to combat SARS-CoV-2 spread is a population-wide vaccination strategy, foremost in those at high risk to develop severe COVID-19 1, 2 . Two types of vaccines have been currently approved by the European Medicines Agency: vector vaccines, such as ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and Ad26.COV2-S (Johnson&Johnson), and mRNA vaccines, such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). However, immune responses to these vaccines vary between individuals and antibody levels wane over time 3, 4 . Application of an additional booster dose is heavily investigated by ongoing clinical trials and first reports have been published [5] [6] [7] [8] . Several countries already started a third vaccination, especially in patients at high risk. Most recently, the United States Food and Drug Administration authorized an additional vaccine dose for certain immunocompromised patients 9 .

Patients under immunosuppressive therapy with rituximab, a B-cell-depleting monoclonal antibody against the CD20 surface antigen, are at a high risk for severe COVID-19 requiring hospitalization and ICU admission 10, 11 . At the same time, B-cell depletion reduces immune responses to vaccination 12, 13 . This combination poses a dilemma and therefore a highly unmet clinical need for this group of patients. Those lacking B lymphocytes in the periphery at the time of vaccination and thus did not yet start reconstituting their B-cell pool often fail to seroconvert 14, 15 . Although B-cell depleted patients can develop a T-cell response, to date, it is unclear to what extent cellular and humoral responses contribute to protection against SARS-CoV-2 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint 4 The development of a humoral immune response currently constitutes a good surrogate of protection, and its absence is therefore often considered an alarm signal for an insufficient vaccination response. In order to stimulate the humoral immune response of rituximab-treated patients who do not respond to the conventional scheme of COVID-19 vaccination, an additional booster vaccination may be an obvious clinical strategy. Recent studies also evaluated the safety and efficacy of homologous versus heterologous schemes for primary and secondary vaccination in healthy individuals [16] [17] [18] . However, it is unknown whether a heterologous approach could benefit those who completely lack a humoral immune response after basic immunization. Furthermore, no data exist on responses to an additional booster vaccination in patients who had completely failed to mount a specific antibody response after the primary two-vaccination schedule.

In this blinded, randomized, controlled trial, we addressed this question and the general inducibility of a humoral or T-cell response in rituximab-treated autoimmune disease patients without anti-SARS-CoV-2 antibodies after their basic mRNA vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint

Sixty-eight patients under rituximab treatment who had been immunized with two doses of mRNA vaccine were screened for eligibility. Eight patients were excluded due to presence of detectable SARS-CoV-2-specific antibodies. 60 nonseroconverted patients were randomized, of whom 30 were assigned to receive vector and 30 to receive mRNA vaccine as the third dose; Five patients withdrew consent between screening and baseline visit (Figure 1) . A total of 27/30 patients were vaccinated with a vector vaccine and 28/30 received an mRNA vaccine. All patients subsequently presented at follow-up visits and completed the trial at week four after vaccination. Patient characteristics were similar between the two randomized groups (Table 1) .

Seroconversion rates at week four were numerically lower in the vector than in the mRNA group (6/27, 22% compared to 9/28, 32% of patients) (Figure 2A . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 4 ). No thrombocytopenia or antibodies against platelet factor 4 (PF4) were observed after additional booster vaccination. None of the patients experienced any anaphylactoid reaction or neurological complication. Seven patients (13%) reported an alteration or worsening in their underlying disease one week after vaccination, but no disease flare that required glucocorticoid treatment or change in immunosuppressive medication was reported within the study period.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Currently approved vector and mRNA vaccination strategies against SARS-CoV-2 consider only homologous vaccination. However, recent studies indicate a better humoral and cellular immune response after heterologous prime-boost vaccination in healthy individuals 16, [18] [19] [20] [21] . In our study, no significant advantage for either the homologous or heterologous vaccination strategy was found: the primary outcome showed a 10% higher seroconversion rate for mRNA (homologous) versus vector (heterologous) vaccination. Conversely, the inducibility of a T-cell response was numerically higher for the vector vaccine. However, while unlikely, these findings statistically cannot rule out a higher efficacy of an additional heterologous versus homologous booster vaccination.

To date, limited data exist that report on the efficacy and safety of a third vaccine in immunosuppressed patients to guide the vaccination strategy on non-seroconverted patients, particularly those at high risk for severe Covid-19 infections. Data published so far report on increased immunogenicity of a third vaccine in patients with solid organ transplantations [6] [7] [8] . However, most of the patients included in these trials had . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The concern with such booster vaccination, also among candidate patients, may mostly relate to the risk of adverse reactions. Although no serious adverse events after booster vaccination were reported in both groups, our data show a numerically higher incidence of adverse events in patients boosted with the heterologous vector than with the homologous mRNA vaccine. These data are in line with recently published reports, which describe an increase in systemic reactogenicity in participants receiving heterologous schedules as compared to homologous schedules 17 . Reactogenicity was similar upon third vaccination as reported previously 16 . In our trial, typical general systemic reactions (like fever, myalgias, and similar) were observed, that were within the scope of the reports from the large . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint 11 approval studies 22-24 , with some numerical differences seen between the two treatment groups.

One limitation of the trial is the absence of a placebo control, which was considered unethical in this high-risk population. While the small sample size precluded delivering ultimate statistical evidence concerning the clinical question of differences in immune responses to booster vaccination with homologous versus heterologous products, the important result of our study is that a third booster vaccination is effective in inducing an immune response in these refractory patients. Since we cannot generalize these data to the wider population of non-responders to COVID-19 vaccines, i.e. beyond immunosuppressed patients, broader population-based programs are needed to evaluate the impact of an additional booster vaccination in non-responding healthy individuals. It is important to note, that it still needs to be determined how humoral and cellular immune responses (or their absence) relate to protection against clinical infection with SARS-CoV-2.

Our data show that a cellular and/or humoral immune response can be achieved upon a third COVID-19 vaccination in most of the patients who initially developed neither a humoral nor a cellular immune response. The efficacy data together with the safety data seen in our trial provide a favorable risk/benefit ratio and support the implementation of a third vaccination for non-seroconverted high-risk autoimmune disease patients treated with B-cell-depleting agents. This might be a viable way to protect this group of patients from more dire consequences of an acquired SARS-CoV-2 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

For T-cell stimulation (see below), PepMix SARS-CoV-2 peptide pools were purchased from JPT (Berlin, Germany). The pools cover the entire sequences of the SARS-CoV-2 S protein and comprise 15-mer peptides overlapping by 11 amino acids (aa). The S peptides are split into two subpools S1 (aa 1-643) and S2 (aa 633-1273). Peptides were dissolved in dimethyl sulfoxide and diluted in AIM-V medium for use in enzyme-linked immunosorbent spot (ELISpot) assays.

For ex vivo T-cell IFN-γ ELISpot assay, PBMCs from patients before and after the third vaccination were thawed and processed on the same day. A total of 1-2×10 5 cells per well were incubated with SARS-CoV-2 peptides (2 µg/mL; duplicates), AIM-V medium (negative control; 3-4 wells) or phytohemagglutinin (PHA) (L4144, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were considered positive if spot counts were greater than the mean SFCs plus three times the standard deviation from pre-pandemic controls, as defined previously 14 .

The primary study endpoint was defined as difference in antibody seroconversion rates between the vector and mRNA vaccinated groups.

Secondary endpoints included seroconversion rate and SARS-CoV-2 antibody levels at week 4 overall and stratified for patients with and without detectable peripheral Bcells as well as cellular immune response defined by T lymphocyte restimulation potential before and one week after vaccination. Safety was reported and evaluated for incidence and severity of adverse events as well as potential effects on the underlying disease activity over a period of 28 days. Additionally, a paper-based patient diary was used. The study sample size was pragmatically targeted at 60 individuals, based on the number of rituximab-treated patients potentially eligible during the tight recruitment period, including estimates of non-responders to a standard protocol of mRNA vaccination, and expected participation rates. Based on a Chi-squared test comparing vector versus mRNA vaccine, this number of patients . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint would allow to achieve at least 80% power at a minimal detectable difference of 28% (5% of responders in one group versus 33% in the other).

All subjects vaccinated with a third dose were included in the analysis. Primary outcome was assessed using Chi-squared test. Secondary outcomes and safety data are presented in a descriptive manner. Post hoc exploratory analyses were performed to evaluate factors associated with seroconversion rates by univariate logistic regression analyses. Variable selection was based on previous data in rituximab patients, and included age, concomitant medication, type of booster vaccination and presence or absence of detectable peripheral B-cells 14 . GraphPad Prism (version 9.1.0) was used for the graphical presentation of the data. "R" version 4.0.3 (R Development Core Team. Vienna, Austria) was used for the entire statistical analysis. Following packages were utilized: "ggplot2", "ggbeeswarm" and "sjPlot" for creating plots and "tableone" to create baseline tables.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. Data are n (%) or mean (SD), csDMARD, conventional synthetic disease modifying antirheumatic drug, defined here as concomitant treatment with at least one of the following: methotrexate, mycophenolate mofetil, azathioprine, leflunomide, hydroxychloroquine.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Seroconversion rate was calculated based on the presence of anti-RBD antibodies in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a testnegative, case-control study

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥ 65 Years -COVID-NET, 13 States

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Correlation of SARS-CoV-2 Breakthrough Infections to Timefrom-vaccine

Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder

doi: medRxiv preprint 21 inducible cellular immune response

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19

a single-blind, randomised, non-inferiority trial. Lancet S0140-6736(21)

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Anti-Spike Protein Assays to Determine SARS-CoV-2

Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

We thank all the patients who participated. We thank Martina Durechova, Daffodil Dioso and Michael Zauner for their support. We thank Brigitte Meyer, Birgit Niederreiter, Carl-Walter Steiner, Ursula Sinzinger, Amelie Popovitsch, JuttaHutecek, Sebastian Weiss, Patrick Mucher, Astrid Radakovics, and Manuela Repl for their technical assistance. We thank Sylvia Taxer, Zoltan Vass, Eva Rath, Nikolaus Hommer, Lisa Göschl and Jochen Zwerina for their support. We thank Franz X.Heinz for critically reading the manuscript.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.09.05.21263125 doi: medRxiv preprint